1.Ciardiello F，Tortora G. EGFR Antagonists in Cancer Treatment . N Engl J Med，2008，358（11）：1160-1174.

2.Yu Z，Boggon TJ，Kobayashi S，et al. Resistance to an irreversible epidermal growth factor receptor（EGFR）inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies. Cancer Res，2007，67（21）：10417-10427.

3.Li D，Ambrogio L，Shimamura T，et al. BIBW2992，an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene，2008，27（34）：4702-4711.

4.Lewis N，Marshall J，Amelsberg A，et al. A phase I dose escalation study of BIBW 2992，an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor，in a 3 week on 1 week off schedule in patients with advanced solid tumors.ASCO Meeting Abstracts，2006，24（18）：3091.

5.Yang C，Shih J，Chao T，et al. Use of BIBW 2992，a novel irreversible EGFR/HER2 TKI，to induce regression in patients with adenocarcinoma of the lung and activating EGFR mutations：Preliminary results of a single-arm phase Ⅱ clinical trial. ASCO Meeting Abstracts，2008，26（15）：8026.

6.Gonzales AJ，Hook KE，Althaus IW，et al. Antitumor activity and pharmacokinetic properties of PF-00299804，a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther，2008，7（7）：1880-1889.

7.Engelman JA，Zejnullahu K，Gale CM，et al. PF00299804，an irreversible pan-ERBB inhibitor，is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to Gefitinib. Cancer Res，2007，67（24）：11924-11932.

8.Janne PA，Schellens JH，Engelman JA，et al. Preliminary activity and safety results from a phase I clinical trial of PF-00299804，an irreversible pan-HER inhibitor，in patients（pts） with NSCLC. ASCO Meeting Abstracts，2008，26（15）：8027.

9.Miller VA，Hirsh V，Cadranel J，et al. Afatinib versus placebo for patients with advanced，metastatic non-smallcell lung cancer after failure of erlotinib，gefitinib，or both，and one or two lines of chemotherapy（LUX-Lung 1）：a phase 2b/3 randomised trial. Lancet Oncol，2012，13（5）：528-538.

10.Yang JC，Shih JY，Su WC，et al.Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations（LUX-Lung 2）：a phase 2 trial. Lancet Oncol，2012，13（5）：539-548.

11.Nelson V，Ziehr J，Agulnik M，et al. Afatinib：emerging next- generation tyrosine kinase inhibitor for NSCLC. Onco Targets There，2013，6：135-143.

12.De Greve J，Teugels E，Geers C，et al. Clinical activity of afatinib（BIBW 2992） in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer，2012，76（1）：123-127.

13.Dungo RT，Keating GM. Afatinib：first global approval. Drugs，2013，73（13）：1503-1515.

14.Sequist LV，Yang JC，Yamamoto N，et al. Phase Ⅲ study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol，2013，31（27）：3327- 3334.

15.Yang JC，Hirsh V，Schuler M，et al. Symptom control and quality of life in LUX-Lung 3：a phase Ⅲ study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol，2013，31（27）：3342-3350.

16.Yun CH，Mengwasser KE，Toms AV，et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA，2008，105（6）：2070-2075.

17.Lee HJ，Schaefer G，Heffron TP，et al. Noncovalent wild-type-sparing inhibitors of EGFR T790M. Cancer Discov，2013，3（2）：168-181.

18.Suda K，Murakami I，Katayama T，et al. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res，2010，16（22）：5489-5498.

19.Byers LA，Diao L，Wang J，et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res，2013，19（1）：279-290.

20.Takezawa K，Pirazzoli V，Arcila ME，et al. HER2 amplification：a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov，2012，2（10）：922-933.

21.Cortot AB，Repellin CE，Shimamura T，et al. Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. Cancer Res，2013，73（2）：834-843.

22.Ranson M，Pao W，Kim D-W，et al. Pre-liminary results from a Phase I study with AZD9291：an irreversible inhibitor of epidermal growth factor receptor（EGFR） activating and resistance mutations in non-small cell lung cancer（NSCLC）. Eur J Cancer，2013，49（suppl 3；abstr LBA33）：S15.

23.Sequist LV，Soria JC，Gadgeel SM，et al. First-in-human evaluation of CO-1686，an irreversible，selective，and potent tyrosine kinase inhibitor of EGFR T790M. J Clin Oncol，2013，31（suppl；abstr 2524）.

24.Soria JC，Sequist LV，Gadgeel S，et al. First-in-human evaluation of CO-1686，an irreversible，highly selective tyrosine kinase inhibitor of mutations of EGFR（activating and T790M）. J Thoracic Oncol，2013，8（Suppl 2；abstr O03.06）：S141.

25.Cortot AB，Repellin CE，Shimamura T，et al. Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. Cancer Res，2013，73（2）：834-843.

26.Su Z，Dias-Santagata D，Duke M，et al. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J Mol Diagn，2011，13（1）：74-84.

27.Ellis PM，Shepherd FA，Millward M，et al. Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer（NCIC CTG BR.26）：a double-blind，randomised，phase 3 trial. Lancet Oncol，2014，15（12）：1379-1388.

28.Soria JC，Felip E，Cobo M，et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung（LUX-Lung 8）：an open-label randomised controlled phase 3 trial. Lancet Oncol，2015，16（8）：897-907.

29.Jänne PA，Yang JC，Kim DW，et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med，2015，372（18）：1689-1699.

30.Thress KS，Paweletz CP，Felip E，et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015，21（6）：560-562.

31.Park K. Updated safety and efficacy results from phase Ⅰ/Ⅱ study of HM61713 in patients（pts） with EGFR mutation positive non-small cell lung cancer（NSCLC） who failed previous EGFR-tyrosine kinase inhibitor（TKI）. J Clin Oncol，2015，33（Suppl 15）：8084.

32.Sequist LV，Goldman JW，Wakelee HA，et al.Efficacy of Rociletinib（CO-1686） in plasma-genotyped T790M-positive NSCLC patients.In：American society of clinical oncology，2015，Abstract 8001.

33.JYPERLIN，Yang JC，Kim DW，et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med，2015，372（18）：1689-1699.

34.Ramalingam SS，Yang JC. AZD9291，a mutant-selective EGFR inhibitor，as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer（NSCLC）：Results from a phase 1 expansion cohort. In：American society of clinical oncology，2015，Abstract 8000.

35.Mitsudomi T，Tsai C，Shepherd F，et al.AZD9291 in pre-treated T790M positive advanced NSCLC：AURA 2 Phase Ⅱ study.Presented at：16 ^th World Conference on Lung Cancer.Abstract 1406.